哮喘与心血管疾病共病的研究进展  

Comorbidity of Asthma and Cardiovascular Disease

作　　者：唐春容 乔卫龙 夏茏[2] 罗琳 罗义钢 TANG Chunrong;QIAO Weilong;XIA Long;LUO Lin;LUO Yigang(Jintang Second People’s Hospital/The Third People’s Hospital of Chengdu,Huaizhou Hospital,Chengdu 610404,Sichuan,China;The Third People’s Hospital of Chengdu,Chengdu 610031,Sichuan,China)

机构地区：[1]金堂县第二人民医院/成都市第三人民医院淮州新城医院,四川成都610404 [2]成都市第三人民医院,四川成都610031

出　　处：《心血管病学进展》2025年第3期225-229,共5页Advances in Cardiovascular Diseases

摘　　要：流行病学证据显示哮喘与多种心血管事件相关,包括动脉粥样硬化性心脏病、心房颤动、心力衰竭等。二者之间的共病机制可能涉及全身性炎症、氧化应激、自主神经功能紊乱以及遗传因素。目前,治疗哮喘与心血管疾病共病尚无特效药物,但一些药物如长效β_(2)受体激动剂、抗胆碱能药、tezepelumab等可能不增加心血管风险,而罗氟司特、度普利尤单抗等药物可能同时对哮喘和心血管疾病有益。现阐述哮喘与心血管疾病的共病风险、机制以及可能的治疗药物,为临床治疗提供一定的思路。Epidemiological evidence indicates that asthma is associated with various cardiovascular events,including atherosclerotic heart disease,atrial fibrillation,heart failure,etc.The potential mechanisms between the two may involve systemic inflammation,oxidative stress,autonomic nervous dysfunction,and genetic factors.Currently,there is no specific drug for the treatment of asthma comorbid with cardiovascular disease,but some medications such as long-acting β_2-agonist,anticholinergic drug,and tezepelumab may not increase cardiovascular risk,while drugs like roflumilast and dupilumab may be beneficial for both asthma and cardiovascular disease.The risk,mechanism and possible therapeutic drugs of comorbidity between asthma and cardiovascular disease are expounded in order to provide some ideas for clinical medical treatment.

关 键 词：哮喘 心血管疾病 共病 机制 

分 类 号：R54[医药卫生—心血管疾病]